Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00403169 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results first posted: Jul 2, 2026 Primary endpoint revised · Enrollment target: estimated 26 to confirmed 28 · Secondary endpoints: 1 to 2v13 Show all 4 changesShow less
    • Primary endpoint revised
    • Enrollment target: estimated 26 to confirmed 28
    • Secondary endpoints: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Active, Not Recruiting to Completed Primary and study completion dates: May 2009 · Study arms: 0 to 1v12 Show all 3 changesShow less
    • Primary and study completion dates: May 2009
    • Study arms: 0 to 1
  3. Lead sponsor: Case Comprehensive Cancer Center to The Cleveland Clinic Collaborators expanded, about 4 wordsv11 Show all 2 changesShow less
    • Collaborators expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  4. 2 versions Re-verified since Jul 23, 2008, no change to tracked fieldsv9-v10
  5. Interventions: antiangiogenesis therapy (Procedure), lenalidomide (Drug) to lenalidomide (Drug)v8
Show 6 earlier versionsHide 6 earlier versions
  1. Re-verified, no change to tracked fieldsv7
  2. Interventions: anti-cytokine therapy (Procedure), antiangiogenesis therapy (Procedure), biological therapy (Procedure), growth factor antagonist therapy… to antiangiogenesis therapy (Procedure), lenalidomide (Drug)v6
  3. Study Status, Eligibilityv5
  4. Trial status: Recruiting to Active, Not Recruiting Site details revisedv4 Show all 2 changesShow less
    • Site details revised
  5. Re-verified, no change to tracked fieldsv3
  6. Eligibility criteria shortened, about 5 words Study description expanded, about 2 words · Study title expanded, about 2 wordsv2 Show all 3 changesShow less
    • Study description expanded, about 2 words
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.
Trial Details
NCT Number NCT00403169
Lead Sponsor The Cleveland Clinic
Collaborators: National Cancer Institute (NCI)
Conditions Kidney Cancer
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov